养血清脑颗粒申报进入越南医药市场的体会  

Research on the application of Yangxue Qingnao Granule as medicinal product in Vietnamese market

作　　者：朱永宏[1] 张万良[1] 赵利斌[1] 赵国骥[1] 郭治昕[1] 

机构地区：[1]天津天士力集团研究院,天津300410

出　　处：《现代药物与临床》2010年第3期229-231,共3页Drugs & Clinic

基　　金：国家"十一五"科技支撑计划资助项目(2006BAI11B00)

摘　　要：越南作为比邻我国的东南亚发展中国家,中医药文化和产品在当地有相当的影响力,中药产品可以作为药品在越南市场销售,亦可进入当地的医疗保险,是我国中医药企业进入国际市场的首选国家和市场之一。天士力集团自2006年起进行了养血清脑颗粒在越南的申报注册,并成功取得证书。以养血清脑颗粒在越南申请处方药的过程为例,简述越南对中药处方药审评的技术要求,提出了开展中药申报的有关思路和观点,为我国中成药企业进入越南市场提供了借鉴,对于我国中成药在越南市场的拓展打下良好的基础。Vietnam is the one of developing countries in Southeast Asia. In Vietnam, traditional Chinese medicines （TCMs） is widely accepted in the mainstream of local pharmaceutical market, and also covered by government reimbursement. As a result, Vietnam is one of the target countries for TCM to launch in the market. Supported by the National Eleventh ＂Five-year＂ Program, Tasly has carried out studies on the application of Yangxue Qingnao Granule in Vietnam. The article has given a brief review on technical requirements of the evaluation of Chinese Proprietary Medicine and indicated relevant ideas and views of the application as an example of prescription drug application in Vietnam. The article has provided good experience for Chinese Proprietary Medicine manufacturers in our country to enter Vietnamese medical market, and also established the foundation for the development of Chinese Proprietary Medicine in Vietnamese market.

关 键 词：养血清脑颗粒 中成药 植物药 越南 申报 

分 类 号：R286[医药卫生—中药学] F740.4[医药卫生—中医学]